发明名称 |
Methods of treatment using human antibody molecules for IL-13 |
摘要 |
Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma. |
申请公布号 |
US9315575(B2) |
申请公布日期 |
2016.04.19 |
申请号 |
US201012941677 |
申请日期 |
2010.11.08 |
申请人 |
MEDIMMUNE LIMITED |
发明人 |
Monk Phillip David;Jermutus Lutz;Shorrock Celia Patricia;Minter Ralph Raymond |
分类号 |
A61K39/395;C07K16/24;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treatment of a disease or disorder selected from the group consisting of asthma, atopic dermatitis, allergic rhinitis, fibrosis and Hodgkin's lymphoma, the method comprising administering a specific binding member to a patient with the disease or disorder, wherein the specific binding member binds interleukin-13 (IL-13) and comprises an antibody antigen-binding site which is composed of a human antibody heavy chain variable region (VH) and a human antibody light chain variable region (VL) comprising a set of complementarity determining regions (CDRs) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein the VH comprises HCDR1, HCDR2 and HCDR3 and the VL comprises LCDR1, LCDR2 and LCDR3, wherein:
HCDR1 comprises SEQ ID NO:7; HCDR2 comprises SEQ ID NO:8; HCDR3 comprises SEQ ID NO:9; LCDR1 comprises SEQ ID NO:10; LCDR2 comprises SEQ ID NO:11; and LCDR3 comprises SEQ ID NO:12. |
地址 |
Cambridge GB |